Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. Sep 27, 2014; 6(9): 652-659
Published online Sep 27, 2014. doi: 10.4254/wjh.v6.i9.652
Published online Sep 27, 2014. doi: 10.4254/wjh.v6.i9.652
Table 1 Characteristics of patients with hepatitis B virus-related hepatocellular carcinoma treated with nucleos(t)ide analogues or not after radical resection
Ref. | Country or region | No. of patient1 | Mean age (yr)1 | TNM stage (I/II/III/IV) (n) | Multiple tumor (%)1 | Mean tumor size (cm)1 | Portal vein invasion (%)1 | Mean HBV-DNA level (log10 copies/mL)1 | Mean ALT (U/L)1 | Cirrhosis (%)1 | Initial treatment for HCC, (Ope/RFA/PEI/TACE) | NA therapy | Mean antiviral treatment duration (mo) | Mean follow-up duration (mo)1 |
Piao et al[21] | Japan | 30 vs 40 | 59 vs 58 | 31/25/11/3 | N/A | 2.3 vs 2.52 | N/A | 6.1 vs 6.52 | 88 vs 62 | N/A | 22/16/0/32 | LAM | N/A | 24 |
Shuqun et al[22] | Chinese mainland | 16 vs 17 | 48.3 vs 48.5 | N/A | N/A | ≥ 5 cm: 56.2% vs 70.6% | 37.5 vs 23.5 | N/A | N/A | 100 vs 94.1 | 33/0/0/0 | LAM | 12 | 12-36 |
Kuzuya et al[23] | Japan | 16 vs 33 | 59.8 vs 61.1 | 25/19/5/0 | N/A | N/A | N/A | 6.2 vs 4.12 | 56.6 vs 54.2 | N/A | 31/18/0/0 | LAM | 22.7 | 38.0 vs 32.6 |
Kubo et al[24] | Japan | 14 vs 10 | 55 vs 55 | 5/9/10/0 | N/A | 2.4 vs 2.8 | 28.6 vs 40.0 | 6.0 vs 6.0 | 53 vs 562 | 42.9 vs 40.0 | 24/0/0/0 | LAM | 32 | 36.7 vs 7.32 |
Hung et al[25] | Hong Kong | 10 vs 62 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 72/0/0/0 | LAM | N/A | 18.92 |
Yoshida et al[26] | Japan | 33 vs 71 | 57 vs 59 | I + II: 57.6% vs 73.2% | N/A | 2.6 vs 2.8 | N/A | ≥ 3.7: 100% vs 63% | 54 vs 362 | N/A | 0/104/0/0 | LAM | N/A | 33 vs 47 |
Koda et al[27] | Japan | 30 vs 20 | 59 vs 60 | 19/20/11/0 | N/A | N/A | N/A | 5.7 vs 5.2 | 78 vs 54 | N/A | 12/24/5/9 | 28LAM + 2ETV | 28.6 | 28.6 vs 36.3 |
Chuma et al[28] | Japan | 20 vs 30 | 55.7 vs 55.6 | 19/27/4/0 | 25.0 vs 23.3 | 1.7 vs 2.1 | N/A | 6.0 vs 5.92 | 43.1 vs 37.7 | 55.0 vs 53.3 | 10/10/0/0 | 15LMA + 5ETV | N/A | 35.5 vs 49.22 |
Li et al[29] | Chinese mainland | 43 vs 36 | 46 vs 45 | 13/27/39/0 | N/A | 7.1 vs 8.5 | 30.2 vs 27.8 | 6.5 vs 7.3 | 60.8 vs 56.5 | 55.8 vs 69.4 | 79/0/0/0 | LAM | N/A | 12 vs 12 |
Chan et al[30] | Hong Kong | 42 vs 94 | 57 vs 552 | 39/32/64/0 | N/A | 9.3 vs 9.02 | 11.9 vs 18.1 | N/A | 58.0 vs 42.52 | 73.8 vs 56.4 | 136/0/0/0 | 38LAM + 4ETV | N/A | N/A |
Wu et al[31] | Tai Wan | 518 vs 4051 | 54.4 vs 54.6 | N/A | N/A | N/A | N/A | N/A | N/A | 48.6 vs 38.7 | 4569/0/0/0 | 159LAM + 292ETV + 36LdT + 31Combined | 17.4 | 31.7 vs 26.2 |
Urata et al[32] | Japan | 46 vs 13 | 57 vs 58 | N/A | 28.3 vs 61.5 | 2.8 vs 3.4 | 34.8 vs 46.2 | 4.7 vs 6.1 | 46.8 vs 58.0 | 45.7 vs 30.8 | 59/0/0/0 | 22LAM + 24ETV | N/A | 36.22 |
Ke et al[33] | Chinese mainland | 141 vs 141 | 48.9 vs 49.7 | N/A | 27.7 vs 24.1 | 4.5 vs 5.02 | 7.8 vs 7.1 | 4.9 vs 4.7 | 39 vs 42 | 81.6 vs 81.6 | 282/0/0/0 | LAM | 12 | 24 vs 23 |
Yin et al[38] | Chinese mainland | 81 vs 82 | 47.9 vs 49.3 | N/A | 12.3 vs 22.0 | ≥ 3 cm: 86.4% vs 93.9% | 3.7 vs 7.3 | 4.9 vs 4.6 | 47.3 vs 37.5 | 24.7 vs 28.0 | 163/0/0/0 | LAM | N/A | 39.92 |
215 vs 402 | 50.1 vs 50.2 | N/A | 14.4 vs 12.7 | ≥ 3 cm: 89.3% vs 92.3% | 14.0 vs 15.4 | 4.5 vs 3.8 | > 42: 48.8% vs 36.8% | 47.0 vs 35.8 | 617/0/0/0 | LAM | N/A | 23.82 | ||
Su et al[34] | Tai Wan | 62 vs 271 | 52 vs 582 | N/A | 22.6 vs 46.9 | 2.7 vs 4.22 | 11.3 vs 20.0 | 5.9 vs 5.52 | 45 vs 422 | 33.7 vs 45.8 | 333/0/0/0 | 40LAM + 19ETV + 3PEG-IFN | N/A | 45.92 |
Yan et al[35] | Chinese mainland | 35 vs 25 | 45 vs 47 | 22/29/9/0 | N/A | 4.7 vs 5.0 | 65.7 vs 68.0 | > 5: 54.3% vs 72.0% | 41.5 vs 35.8 | N/A | 60/0/0/0 | LAM | N/A | N/A |
Hann et al[37] | The United States | 16 vs 9 | 57 vs 532 | N/A | 0 vs 0 | 2.7 vs 3.02 | 0 vs 0 | 5.4 vs 6.92 | N/A | N/A | 3/4/2/8/others3 | 8(LAM + TDF) + 3(LAM + ADV) + 2(TLV + TDF) + 2TDF + 1LAM | N/A | 60.2 |
Huang et al[39] | Chinese mainland | 100 vs 100 | 50.6 vs 50.5 | N/A | 17 vs 16 | 4.9 vs 5.1 | 0 vs 0 | > 3.3: 100% vs 100% | 52.6 vs 51.4 | N/A | 200/0/0/0 | ADV | N/A | 602 |
Table 2 Survival outcomes of patients with hepatitis B virus-related hepatocellular carcinoma treated with nucleos(t)ide analogues or not after radical resection
Year ofpublication | Ref. | Group | n | Overall survival rate (%) | Recurrence-free survival rate (%) | ||||||
1 yr | 3 yr | 5 yr | P | 1 yr | 3 yr | 5 yr | P | ||||
2005 | Piao et al[21] | NAs | 30 | 100 | 91.3 | N/A | 0.12 | 75 | 46 | N/A | > 0.05 |
Control | 40 | 92.4 | 66 | N/A | 58 | 22 | N/A | ||||
2006 | Shuqun et al[22] | NAs | 16 | 24 | N/A | N/A | 0.0053 | 19.7 | N/A | N/A | > 0.05 |
Control | 17 | 0 | N/A | N/A | 4.5 | N/A | N/A | ||||
2007 | Kuzuya et al[23] | NAs | 16 | 100 | 100 | N/A | 0.063 | 86.5 | 64.9 | N/A | 0.622 |
Control | 33 | 86.6 | 46.8 | N/A | 86.6 | 46.8 | N/A | ||||
2007 | Kubo et al[24] | NAs | 14 | N/A | N/A | N/A | N/A | 90 | 90 | 78 | 0.0086 |
Control | 10 | N/A | N/A | N/A | 55 | 28 | 28 | ||||
2008 | Hung et al[25] | NAs | 10 | N/A | N/A | N/A | N/A | 90 | N/A | N/A | 0.03 |
Control | 62 | N/A | N/A | N/A | 75 | N/A | N/A | ||||
2008 | Yoshida et al[26] | NAs | 33 | 100 | 80 | 59 | > 0.05 | N/A | N/A | N/A | > 0.05 |
Control | 71 | 100 | 85 | 70 | N/A | N/A | N/A | ||||
2009 | Koda et al[27] | NAs | 30 | 96 | 76 | 76 | 0.02 | 65 | 15 | N/A | > 0.05 |
Control | 20 | 86 | 48 | 32 | 72 | 30 | N/A | ||||
2009 | Chuma et al[28] | NAs | 20 | N/A | N/A | N/A | N/A | 90 | 55 | 45 | > 0.05 |
Control | 64 | N/A | N/A | N/A | 85.9 | 50 | 43.7 | ||||
2010 | Li et al[29] | NAs | 43 | 41.9 | N/A | N/A | 0.0094 | 23.3 | N/A | N/A | 0.072 |
Control | 36 | 33.3 | N/A | N/A | 8.3 | N/A | N/A | ||||
2011 | Chan et al[30] | NAs | 42 | 88.1 | 79.1 | 71.2 | 0.005 | 66.5 | 51.4 | 51.4 | 0.05 |
Control | 94 | 76.5 | 47.5 | 43.5 | 48.9 | 33.8 | 33.8 | ||||
2012 | Wu et al[31] | NAs | 518 | 94 | 81 | 73 | 0.002 | 87 | 66 | 54 | < 0.001 |
Control | 4051 | 91 | 74 | 62 | 78 | 56 | 47 | ||||
2012 | Urata et al[32] | NAs | 46 | 100 | 97.1 | 89.7 | 0.0025 | 71.6 | 56.8 | 42.6 | 0.0478 |
Control | 13 | 84.6 | 68.4 | 59.8 | 61.5 | 19.2 | 19.2 | ||||
2013 | Ke et al[33] | NAs | 141 | 92.1 | 84.4 | 79.1 | 0.009 | 73.1 | 54.7 | 44.5 | 0.503 |
Control | 141 | 89.6 | 66.3 | 52.1 | 68.8 | 47.8 | 43 | ||||
2013 | Yin et al[38] | NAs | 81 | 98 | 88 | N/A | < 0.001 | 81 | 46 | N/A | < 0.001 |
Control | 82 | 86 | 51 | N/A | 50 | 20 | N/A | ||||
NAs | 215 | 84 | 60 | N/A | 0.04 | 52 | 37.5 | N/A | < 0.001 | ||
Control | 402 | 75 | 50 | N/A | 43 | 21 | N/A | ||||
2013 | Su et al[34] | NAs | 62 | 99 | 96 | 89 | < 0.001 | 90 | 64 | 58 | < 0.001 |
Control | 271 | 84 | 64 | 49 | 64 | 44 | 34 | ||||
2013 | Yan et al[35] | NAs | 35 | N/A | N/A | N/A | N/A | 74.3 | 11.4 | N/A | 0.283 |
Control | 25 | N/A | N/A | N/A | 80 | 0 | N/A | ||||
2014 | Hann et al[37] | NAs | 16 | 100 | 93.8 | 86.5 | < 0.001 | 81.3 | 81.3 | 81.3 | < 0.001 |
Control | 9 | 55.6 | 0 | 0 | 11.1 | 0 | 0 | ||||
2014 | Huang et al[39] | NAs | 100 | 96 | 77.6 | 63.1 | 0.001 | 85 | 50.3 | 46.1 | 0.026 |
Control | 100 | 94 | 67.4 | 41.5 | 84 | 37.9 | 27.1 |
Table 3 Mutations of the hepatitis B virus polymerase gene arising after initial therapy with one nucleos(t)ide analogue and resulting in cross-resistance to other nucleos(t)ide analogues
- Citation: Ke Y, Wang L, Li LQ, Zhong JH. Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection. World J Hepatol 2014; 6(9): 652-659
- URL: https://www.wjgnet.com/1948-5182/full/v6/i9/652.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i9.652